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Up to 60% of depressed patients do not respond comple-
tely to antidepressants and up to 30% do not respond at
all. Among the many reasons leading to non-response,
such as inadequate treatments and comorbid conditions,
genetic factors as likely to contribute to up to 50% of var-
iance in antidepressant response. Environmental factors,
such as chronic stressors, psychosocial adjustment and
personality traits may also influence response to treat-
ment and interact with these. The investigation of both
of these types of factors has been informative in genetic
aetiological studies (e.g. Caspi et al., 2003) and is increas-
ingly employed in pharmacogenetics.
A growing number of genetic variants have been repli-
cated in terms of association with SSRI efficacy. They
include polymorphisms in the serotonin transporter gene
(5-HTTLPR), tryptophan hydroxylase gene (TPH),
5HT1A and 5HT2A receptors, the G-protein beta3-
subunit (GNB3), Catechol-O-methyltransferase (COMT),
the noradrenaline transporter (NAT), and dystrobrevin
binding protein 1 (DTNBP1). Data indicating environ-
mental stressors and temperamental traits as moderators
of the effect of such genes on response to treatment will
also be presented.
In conclusion, there are genetic and environmental
factors that interact in a complex manner to impact on
response to treatment with antidepressants. Increased
understanding of these, including clinical characteristics
such as “harm avoidance,” may assist the clinician in
deciding the best antidepressant to prescribe for a given
patient.
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